The Neurologic Oncology Program comprises 22 members, drawn from 9 different departments, representing fundamental laboratory research in the origins and molecular basis of brain tumors, neurooncologists, radiologists and neurosurgeons who take a team approach to the improvement of brain cancer therapy, and population scientists working on brain cancer epidemiology. Research goals include understanding how brain cancers relate to neural stem cells, the relationship between brain tumors and their stromal environment and their vasculature, and a better understanding of altered signaling pathways. These new insights are being translated into improved therapies for patients suffering from brain cancer, along with innovative methods of detecting tumors and of drug delivery. This group of investigators is both highly productive and interactive. Their publications include works published in Nature, Cancer Cell, Nature Cell Biology, Nature Genetics, New England Journal of Medicine, Journal of Clinical Oncology, and Nature Medicine. The broad range of publications covering population science, cell signaling, genomics, imaging, and clinical science, as well as the high percentage of intra- and inter-programmatic publications, are the result of a strategically integrated, highly interactive, diverse, and productive Program that continues to make significant progress in reaching its stated goals. The Program has $8,795,681 Total peer reviewed support for the last budget year. The Program has 33% intra-programmatic and 38% inter-programmatic publications.
| Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131: |
| Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228 |
| Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408 |
| Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279 |
| Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380 |
| Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485 |
| An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575 |
| Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3: |
| Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607 |
| An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794 |
Showing the most recent 10 out of 192 publications
